Instrument NameEli Lilly and CompanyInstrument Symbol(LLY-N)

Instrument ExchangeNYSE

The future keeps getting brighter for these companies.

Its latest medicines for obesity and type 2 diabetes are selling rapidly.

Both of these businesses are finding traction in a pair of major markets.

Eli Lilly just took a page out of Novo Nordisk's book.

These three companies have track records that should please investors.

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

This mid-cap biopharma may one day be a titan of the industry.

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market - and one company is set to dominate this field.

It's hard to bet against this high-flying stock.

These pharmaceutical companies are top-notch dividend growth stocks for the future.

Kathrin Forrest of global investment firm Capital Group says her firm is focused on infrastructure and power companies that benefit from the rising use of artificial intelligence

Turn small investments into big returns with this surprisingly simple strategy -- and a hands-off ETF investment for the ages.

SAN DIEGO, CA - (NewMediaWire) - May 07, 2024 - Sigyn Therapeutics, Inc. (“Sigyn Therapeutics”, “Sigyn” or the “Company”) (OTCQB: “SIGY”), a development-stage medical technology company, announced today that it has published an article entitled:...

Here are a couple of great ideas on where to invest your money today.

These stocks have rock-solid businesses and they have impressive track records for paying dividends.

These great stocks are great picks for investors as spring winds down.

Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.

Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.

The anti-obesity medication stock is way up, and there could be more fuel in the tank.

The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.

The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.

The company seems to be going from strength to strength lately.

The biggest healthcare company in the world could grow much larger over the next decade.

The billionaire's family fund is surprisingly concentrated.